Oppenheimer Asset Management Inc. Has $1.30 Million Holdings in Edwards Lifesciences Co. (NYSE:EW)

Oppenheimer Asset Management Inc. boosted its position in shares of Edwards Lifesciences Co. (NYSE:EW) by 37.3% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 17,574 shares of the medical research company’s stock after acquiring an additional 4,770 shares during the period. Oppenheimer Asset Management Inc.’s holdings in Edwards Lifesciences were worth $1,301,000 at the end of the most recent quarter.

Other hedge funds also recently bought and sold shares of the company. FSA Wealth Management LLC bought a new position in shares of Edwards Lifesciences in the third quarter worth about $30,000. Migdal Insurance & Financial Holdings Ltd. acquired a new stake in Edwards Lifesciences in the 4th quarter valued at approximately $30,000. Prospera Private Wealth LLC bought a new position in Edwards Lifesciences in the 3rd quarter worth approximately $32,000. Avior Wealth Management LLC lifted its holdings in shares of Edwards Lifesciences by 138.7% during the third quarter. Avior Wealth Management LLC now owns 530 shares of the medical research company’s stock worth $35,000 after buying an additional 308 shares during the last quarter. Finally, Roble Belko & Company Inc bought a new stake in shares of Edwards Lifesciences in the fourth quarter valued at approximately $46,000. 79.46% of the stock is currently owned by institutional investors.

Insider Buying and Selling

In other Edwards Lifesciences news, VP Daniel J. Lippis sold 2,500 shares of the stock in a transaction on Monday, December 16th. The stock was sold at an average price of $74.08, for a total value of $185,200.00. Following the transaction, the vice president now directly owns 23,189 shares in the company, valued at approximately $1,717,841.12. This trade represents a 9.73 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CFO Scott B. Ullem sold 11,250 shares of Edwards Lifesciences stock in a transaction on Thursday, February 13th. The shares were sold at an average price of $75.76, for a total value of $852,300.00. Following the completion of the sale, the chief financial officer now directly owns 30,561 shares of the company’s stock, valued at $2,315,301.36. This trade represents a 26.91 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 37,739 shares of company stock worth $2,799,104 in the last 90 days. Corporate insiders own 1.29% of the company’s stock.

Edwards Lifesciences Stock Performance

NYSE EW opened at $71.37 on Tuesday. The firm has a market cap of $42.09 billion, a price-to-earnings ratio of 10.24, a PEG ratio of 4.82 and a beta of 1.10. The company has a current ratio of 3.46, a quick ratio of 2.89 and a debt-to-equity ratio of 0.06. Edwards Lifesciences Co. has a 1-year low of $58.93 and a 1-year high of $96.12. The company has a 50 day moving average of $72.58 and a 200-day moving average of $70.32.

Edwards Lifesciences (NYSE:EW) last released its quarterly earnings results on Tuesday, February 11th. The medical research company reported $0.59 earnings per share for the quarter, beating analysts’ consensus estimates of $0.55 by $0.04. Edwards Lifesciences had a return on equity of 19.40% and a net margin of 72.93%. On average, equities analysts forecast that Edwards Lifesciences Co. will post 2.45 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of equities analysts recently issued reports on the stock. Stifel Nicolaus raised shares of Edwards Lifesciences from a “hold” rating to a “buy” rating and boosted their target price for the stock from $75.00 to $90.00 in a research report on Thursday, January 30th. Citigroup boosted their price objective on shares of Edwards Lifesciences from $81.00 to $83.00 and gave the stock a “buy” rating in a report on Wednesday, December 11th. Royal Bank of Canada reiterated an “outperform” rating and issued a $85.00 target price on shares of Edwards Lifesciences in a research note on Wednesday, February 12th. Barclays boosted their price target on Edwards Lifesciences from $88.00 to $90.00 and gave the company an “overweight” rating in a research note on Thursday, February 13th. Finally, The Goldman Sachs Group raised their price objective on Edwards Lifesciences from $81.00 to $90.00 and gave the stock a “buy” rating in a research report on Thursday, December 5th. One investment analyst has rated the stock with a sell rating, fourteen have given a hold rating and twelve have given a buy rating to the company. According to MarketBeat.com, the company currently has an average rating of “Hold” and a consensus target price of $79.95.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.